vs
Apellis Pharmaceuticals, Inc.（APLS）与WESBANCO INC（WSBC）财务数据对比。点击上方公司名可切换其他公司
WESBANCO INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$257.2M vs $199.9M），WESBANCO INC净利率更高（34.5% vs -29.5%，领先63.9%），过去两年WESBANCO INC的营收复合增速更高（31.9% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
WesBanco是一家总部位于美国西弗吉尼亚州惠灵的银行控股公司，业务覆盖广泛，目前在西弗吉尼亚州、俄亥俄州、宾夕法尼亚州西部、肯塔基州、马里兰州及印第安纳州南部拥有超过200家营业网点，为当地客户提供多元金融服务。
APLS vs WSBC — 直观对比
营收规模更大
WSBC
是对方的1.3倍
$199.9M
净利率更高
WSBC
高出63.9%
-29.5%
两年增速更快
WSBC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $257.2M |
| 净利润 | $-59.0M | $88.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 34.5% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | 54.4% |
| 每股收益（稀释后） | $-0.40 | $0.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSWSBC
| Q1 26 | — | $257.2M | ||
| Q4 25 | $199.9M | $265.6M | ||
| Q3 25 | $458.6M | $261.6M | ||
| Q2 25 | $178.5M | $260.7M | ||
| Q1 25 | $166.8M | $193.2M | ||
| Q4 24 | $212.5M | $162.9M | ||
| Q3 24 | $196.8M | $150.8M | ||
| Q2 24 | $199.7M | $147.9M |
净利润APLSWSBC
| Q1 26 | — | $88.6M | ||
| Q4 25 | $-59.0M | $91.1M | ||
| Q3 25 | $215.7M | $83.6M | ||
| Q2 25 | $-42.2M | $57.4M | ||
| Q1 25 | $-92.2M | $-9.0M | ||
| Q4 24 | $-36.4M | $49.6M | ||
| Q3 24 | $-57.4M | $37.3M | ||
| Q2 24 | $-37.7M | $28.9M |
营业利润率APLSWSBC
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 43.2% | ||
| Q3 25 | 48.7% | 39.5% | ||
| Q2 25 | -18.6% | 27.2% | ||
| Q1 25 | -50.0% | -5.0% | ||
| Q4 24 | -12.3% | 38.0% | ||
| Q3 24 | -24.0% | 29.7% | ||
| Q2 24 | -14.7% | 23.7% |
净利率APLSWSBC
| Q1 26 | — | 34.5% | ||
| Q4 25 | -29.5% | 34.3% | ||
| Q3 25 | 47.0% | 31.9% | ||
| Q2 25 | -23.6% | 22.0% | ||
| Q1 25 | -55.3% | -4.7% | ||
| Q4 24 | -17.1% | 30.5% | ||
| Q3 24 | -29.2% | 24.7% | ||
| Q2 24 | -18.9% | 19.5% |
每股收益（稀释后）APLSWSBC
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-0.40 | $0.97 | ||
| Q3 25 | $1.67 | $0.84 | ||
| Q2 25 | $-0.33 | $0.57 | ||
| Q1 25 | $-0.74 | $-0.15 | ||
| Q4 24 | $-0.30 | $0.72 | ||
| Q3 24 | $-0.46 | $0.54 | ||
| Q2 24 | $-0.30 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $4.1B |
| 总资产 | $1.1B | $27.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSWSBC
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | $956.1M | ||
| Q3 25 | $479.2M | $1.0B | ||
| Q2 25 | $370.0M | $1.2B | ||
| Q1 25 | $358.4M | $1.1B | ||
| Q4 24 | $411.3M | $568.1M | ||
| Q3 24 | $396.9M | $620.9M | ||
| Q2 24 | $360.1M | $486.8M |
股东权益APLSWSBC
| Q1 26 | — | $4.1B | ||
| Q4 25 | $370.1M | $4.0B | ||
| Q3 25 | $401.2M | $4.1B | ||
| Q2 25 | $156.3M | $3.8B | ||
| Q1 25 | $164.2M | $3.8B | ||
| Q4 24 | $228.5M | $2.8B | ||
| Q3 24 | $237.1M | $2.8B | ||
| Q2 24 | $264.3M | $2.5B |
总资产APLSWSBC
| Q1 26 | — | $27.5B | ||
| Q4 25 | $1.1B | $27.7B | ||
| Q3 25 | $1.1B | $27.5B | ||
| Q2 25 | $821.4M | $27.6B | ||
| Q1 25 | $807.3M | $27.4B | ||
| Q4 24 | $885.1M | $18.7B | ||
| Q3 24 | $901.9M | $18.5B | ||
| Q2 24 | $904.5M | $18.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSWSBC
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $290.4M | ||
| Q3 25 | $108.5M | $116.9M | ||
| Q2 25 | $4.4M | $105.0M | ||
| Q1 25 | $-53.4M | $-26.4M | ||
| Q4 24 | $19.4M | $211.0M | ||
| Q3 24 | $34.1M | $60.7M | ||
| Q2 24 | $-8.3M | $18.2M |
自由现金流APLSWSBC
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $280.0M | ||
| Q3 25 | $108.3M | $114.9M | ||
| Q2 25 | $4.4M | $98.3M | ||
| Q1 25 | $-53.4M | $-30.7M | ||
| Q4 24 | $19.3M | $200.7M | ||
| Q3 24 | — | $56.9M | ||
| Q2 24 | $-8.4M | $17.3M |
自由现金流率APLSWSBC
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 105.4% | ||
| Q3 25 | 23.6% | 43.9% | ||
| Q2 25 | 2.5% | 37.7% | ||
| Q1 25 | -32.0% | -15.9% | ||
| Q4 24 | 9.1% | 123.2% | ||
| Q3 24 | — | 37.7% | ||
| Q2 24 | -4.2% | 11.7% |
资本支出强度APLSWSBC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.9% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 6.3% | ||
| Q3 24 | 0.0% | 2.5% | ||
| Q2 24 | 0.0% | 0.6% |
现金转化率APLSWSBC
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | 0.50× | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
